The company is a clinical-stage I&I platform company developing a first-in-class oral EP4 agonist that rebalances immune overactivation across oncology, cell therapy, and chronic inflammatory disease. Early Phase 1b/2a data in CAR-T patients at risk for CRS/ICANS show no interference with CAR-T efficacy, signs of improved expansion and tumor outcomes, and a favorable safety profile. With multi-indication potential and an >$8B market, the company is raising $30M to advance the ongoing Phase 1b/2a CRS trial in lymphoma and Phase II programs in asthma and atopic dermatitis. programs and is seeking investors and strategic pharma partners.